Business Segments Revolution Medicines, Inc.
Equities
RVMD
US76155X1000
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.31 USD | -1.05% |
|
-0.44% | +20.92% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Biotechnology | 42.98M | 29.39M | 35.38M | 11.58M | - | |||
Total Assets | 567M | 738M | 812M | 2.06B | 2.56B | |||
Interest Expense | -71K | -12K | - | -303K | - | |||
Income Tax Expense | -371K | - | -420K | -3.52M | -753K | |||
CAPEX | -2.93M | -6.53M | -10.82M | -7.73M | -10.31M | |||
EBT | -109M | -187M | -249M | -440M | -601M | |||
D&A | 5.44M | 6.23M | 8.56M | 8.21M | 10.72M | |||
Operating Income | -111M | -188M | -258M | -487M | -690M | |||
Net Income | -108M | -187M | -249M | -436M | -600M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
United States | 42.98M | 29.39M | 35.38M | 11.58M | - | |||
Total Assets | 567M | 738M | 812M | 2.06B | 2.56B | |||
Interest Expense | -71K | -12K | - | -303K | - | |||
Income Tax Expense | -371K | - | -420K | -3.52M | -753K | |||
D&A | 5.44M | 6.23M | 8.56M | 8.21M | 10.72M | |||
CAPEX | -2.93M | -6.53M | -10.82M | -7.73M | -10.31M | |||
Net Income | -108M | -187M | -249M | -436M | -600M | |||
EBT | -109M | -187M | -249M | -440M | -601M | |||
Operating Income | -111M | -188M | -258M | -487M | -690M |
- Stock Market
- Equities
- RVMD Stock
- Financials Revolution Medicines, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition